- Home
- URGN vs CRDF Comparison
URGN vs CRDF Comparison
Compare URGN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- CRDF
- Stock Information
- Founded
- URGN 2004
- CRDF 1999
- Country
- URGN United States
- CRDF United States
- Employees
- URGN N/A
- CRDF N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- URGN Health Care
- CRDF Health Care
- Exchange
- URGN Nasdaq
- CRDF Nasdaq
- Market Cap
- URGN 181.2M
- CRDF 169.6M
- IPO Year
- URGN 2017
- CRDF N/A
- Fundamental
- Price
- URGN $14.82
- CRDF $3.18
- Analyst Decision
- URGN Strong Buy
- CRDF Strong Buy
- Analyst Count
- URGN 9
- CRDF 4
- Target Price
- URGN $26.81
- CRDF $12.25
- AVG Volume (30 Days)
- URGN 5.9M
- CRDF 1.2M
- Earning Date
- URGN 08-12-2025
- CRDF 08-07-2025
- Dividend Yield
- URGN N/A
- CRDF N/A
- EPS Growth
- URGN N/A
- CRDF N/A
- EPS
- URGN N/A
- CRDF N/A
- Revenue
- URGN $91,871,000.00
- CRDF $587,000.00
- Revenue This Year
- URGN $36.65
- CRDF N/A
- Revenue Next Year
- URGN $88.35
- CRDF N/A
- P/E Ratio
- URGN N/A
- CRDF N/A
- Revenue Growth
- URGN 8.98
- CRDF N/A
- 52 Week Low
- URGN $3.42
- CRDF $2.01
- 52 Week High
- URGN $18.15
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- URGN 73.80
- CRDF 41.74
- Support Level
- URGN $6.92
- CRDF $2.98
- Resistance Level
- URGN $15.22
- CRDF $3.99
- Average True Range (ATR)
- URGN 1.57
- CRDF 0.29
- MACD
- URGN 1.17
- CRDF -0.08
- Stochastic Oscillator
- URGN 96.49
- CRDF 5.34
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.